Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Feb;56(2):209-210.
doi: 10.1007/s40262-016-0493-1.

Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study"

Stephan Glund  1 , Paul Reilly  2 , Joanne van Ryn  3 , Joachim Stangier  3
Affiliations
Comment

Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study"

Stephan Glund et al. Clin Pharmacokinet. 2017 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards Conflicts of interest Stephan Glund, Joanne van Ryn, and Joachim Stangier are employees of Boehringer Ingelheim Pharma GmbH & Co. KG. Paul Reilly is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. Funding None received.

Comment on

References

    1. Kamel KS, Chin PK, Doogue MP, Barclay ML. Comment on: “Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase ib study”. Clinic Pharmacokinet. 2017. doi10.1007/s40262-016-0481-5. - PubMed
    1. Pollack CV, Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520. doi: 10.1056/NEJMoa1502000. - DOI - PubMed
    1. PRAXBIND prescribing information 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf. Accessed 3 Nov 2016.
    1. Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943–951. doi: 10.1160/TH14-12-1080. - DOI - PubMed
    1. Glund S, Stangier J, van Ryn J, Schmohl M, Moschetti V, Haazen W, et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib Study. Clin Pharmacokinet. Epub. 2016 - PMC - PubMed

LinkOut - more resources